文献速递胸部肿瘤

接受细胞毒性化疗联合纳武利尤单抗加伊匹木单抗患者中五例细胞因子释放综合征:病例报告

Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report.
PubMed 文献 · J Thorac Oncol · 2023-11-07

一项III期临床试验在初治晚期非小细胞肺癌患者中比较铂类联合化疗联合纳武利尤单抗加伊匹木单抗与铂类联合化疗联合帕博利珠单抗的疗效,因纳武利尤单抗加伊匹木单抗组治疗相关死亡比例高而提前终止,该组148例中发生5例(3.4%)细胞因子释放综合征(CRS),其中3例死亡,本文报告这5例的细节。

要点

  • 纳武利尤单抗加伊匹木单抗组148例中发生5例(3.4%)CRS,其中3例治疗相关死亡归因于CRS。
  • 5例CRS患者起病时间与背景不同,但均在CRS出现前观察到发热。
  • 肿瘤内科医生应知晓纳武利尤单抗加伊匹木单抗治疗期间出现发热可能预示CRS发生。

核心结论

  • 在初治晚期非小细胞肺癌的III期试验中,纳武利尤单抗加伊匹木单抗联合铂类化疗组出现5例(3.4%)CRS,其中3例为治疗相关死亡;5例均在CRS出现前有发热,作者提醒肿瘤内科医生发热可能预示CRS。

研究设计与样本

  • III期临床试验,比较铂类联合化疗联合纳武利尤单抗加伊匹木单抗与铂类联合化疗联合帕博利珠单抗在初治晚期非小细胞肺癌患者中的疗效;因纳武利尤单抗加伊匹木单抗组治疗相关死亡比例高,在治疗295例后提前终止;本文为其中5例CRS的病例报告。

主要发现

  • 纳武利尤单抗加伊匹木单抗组148例患者中发生5例(3.4%)CRS,其中3例治疗相关死亡归因于CRS;另2例CRS得到有效处理;5例患者背景和CRS起病时间不同,但均在CRS出现前观察到发热。

临床怎么用

  • 作者提醒肿瘤内科医生,纳武利尤单抗加伊匹木单抗治疗期间出现发热可能预示CRS发生。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We conducted a phase 3 clinical trial to compare the efficacy of platinum-based combination chemotherapy together with nivolumab plus ipilimumab relative to that of platinum-based combination chemotherapy together with pembrolizumab in previously untreated patients with advanced NSCLC. The trial was terminated prematurely after treatment of 295 patients because of a high proportion of treatment-related deaths, three of which were due to cytokine release syndrome (CRS), in the nivolumab plus ipilimumab treatment arm. In addition, we encountered two cases of CRS that were effectively managed, for a total of five cases (3.4%) among the 148 patients in the nivolumab plus ipilimumab arm. We here provide details of these five cases. Although patient background and timing of CRS onset differed, fever was observed before the emergence of CRS in all five cases. Oncologists should thus be aware that the development of fever during treatment of patients with nivolumab plus ipilimumab may herald the onset of CRS.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Shiraishi Y, Tokito T, Toyozawa R, et al. Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report. J Thorac Oncol. 2023. PMID: 37943237. doi:10.1016/j.jtho.2023.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。